In patients with concomitant severe MR and TR, significant TR reduction after isolated M-TEER occurred in only 42% of patients, with MR grade reduction ≥3+ being the only independent predictor.
Observational (n=107)
Yes
Does mitral transcatheter edge-to-edge repair (M-TEER) reduce severe tricuspid regurgitation in patients with concomitant severe MR and TR?
In patients with concomitant severe MR and TR, isolated M-TEER reduces TR in only ~40% of cases, suggesting that dedicated transcatheter tricuspid therapies should be considered in heart-team discussions.
BackgroundSevere tricuspid regurgitation (TR) may persist after a mitral transcatheter edge-to-edge repair (M-TEER) and is associated with worsened clinical outcomes and survival. It is unclear which patients with concomitant mitral regurgitation (MR) and TR will have TR reduction after M-TEER. The aim of this study was to identify the predictors of residual TR after transcatheter edge-to-edge repair (TEER).MethodsData were collected from the Northwell TEER registry, a prospectively maintained mandatory database including 4 high-volume transcatheter aortic valve replacement/TEER centers. Transthoracic echocardiograms, both pre-TEER and post-TEER, were evaluated. Univariate and multivariate logistic regression analyses were performed to identify predictors of severe TR after M-TEER. Significant TR reduction was defined as a reduction in TR grade by at least 1+ with moderate (2+) or less TR at 1 month.ResultsOf the 479 patients who underwent M-TEER, 107 patients with concomitant severe MR/TR were included. Successful MR reduction occurred in 89 patients (84%) and a significant TR reduction in 45 (42%). On the univariate analysis, the only predictors of severe residual TR were right atrial area and unsuccessful M-TEER. On the multivariate logistic regression model, the only predictor variable for patients with a reduction in TR was MR reduction of ≥3+ with M-TEER.ConclusionsIn patients with concomitant severe MR and TR, TR reduction after isolated M-TEER occurs in only ∼40% of patients. MR grade reduction ≥3+ was the only independent predictor for TR reduction. Other clinical and echocardiographic variables (including pulmonary hypertension, right ventricular function, tricuspid annular dilation, atrial fibrillation, and presence of a cardiac implantable electrical device) were not associated with residual TR. Inability to predict TR reduction after M-TEER highlights the importance of establishing transcatheter tricuspid valve therapies and should factor in heart-team discussions.
Basman et al. (Fri,) conducted a observational in Concomitant severe mitral regurgitation (MR) and tricuspid regurgitation (TR) (n=107). Mitral transcatheter edge-to-edge repair (M-TEER) was evaluated on Significant TR reduction (reduction in TR grade by at least 1+ with moderate (2+) or less TR at 1 month). In patients with concomitant severe MR and TR, significant TR reduction after isolated M-TEER occurred in only 42% of patients, with MR grade reduction ≥3+ being the only independent predictor.